Autophagy Inhibition Potentiates the Anticancer Effects of a Bendamustine Derivative NL-101 in Acute T Lymphocytic Leukemia

Autophagy Inhibition Potentiates the Anticancer Effects of a Bendamustine Derivative NL-101 in Acute T Lymphocytic Leukemia

Acute T lymphocytic leukemia (T-ALL) is an aggressive hematologic resulting from the malignant transformation of T-cell progenitors. Drug resistance and relapse are major difficulties in the treatment of T-ALL. Here, we report the antitumor potency of NL-101, a compound that combines the nitrogen mu...

Full description

Bibliographic Details
Main Authors:	Hang Gao, Siyue Lou, Huanwu Hong, Qiufu Ge, Huajun Zhao
Format:	Article
Language:	English
Published:	Hindawi Limited 2020-01-01
Series:	BioMed Research International
Online Access:	http://dx.doi.org/10.1155/2020/1520651

Similar Items

Role of bendamustine in the treatment of chronic lymphocytic leukemia
by: Saad Jamshed, et al.
Published: (2009-03-01)

The expanding role of bendamustine in chronic lymphocytic leukemia
by: Nair KS, et al.
Published: (2015-07-01)

Inhibition of STAT3 by Anticancer Drug Bendamustine.
by: Kazunori Iwamoto, et al.
Published: (2017-01-01)

Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia
by: Sara E. F. Kost, et al.
Published: (2019-10-01)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
by: Steven E. Coutre, et al.
Published: (2018-06-01)

Inhibition of retinoic acid receptor α phosphorylation represses the progression of triple-negative breast cancer via transactivating miR-3074-5p to target DHRS3
by: Siyue Lou, et al.
Published: (2021-04-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Combination of bendamustine and rituximab in the management of relapsed and refractory chronic lymphocytic leukemia: the results of retrospective study
by: S. V. Semochkin, et al.
Published: (2015-06-01)

Bendamustine: an Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
by: Martina Bogeljić Patekar, et al.
Published: (2018-01-01)

Cytotoxic and apoptosis-inducing effects of bendamustine used alone and in combination with rituximab on chronic lymphocytic leukemia cells in vitro
by: Ewelina Ziolkowska, et al.
Published: (2014-12-01)

Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab
by: Shinya Rai, et al.
Published: (2018-09-01)

Efficacy of a bendamustine and rituximab combination in first-line therapy for chronic lymphocytic leukemia: Results of the BEN-001 study
by: E A Stadnik, et al.
Published: (2017-07-01)

Bendamustine-induced immune hemolytic anemia in a chronic lymphocytic leukemia patient: A case report and review of the literature
by: Housam Haddad, et al.
Published: (2014-12-01)

Budgetary Impact of Bendamustine Ready-to-Dilute Products in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma to a United States Infusion Facility
by: James E, et al.
Published: (2021-03-01)

Minimal Residual Disease and IGHV-Genes Mutational Status as the Main Predictors of Response to Bendamustine-Rituximab Therapy in Previously Untreated Chronic Lymphocytic Leukemia
by: YuV Mirolyubova, et al.
Published: (2018-04-01)

Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis
by: Kongnakorn T, et al.
Published: (2014-04-01)

The molecular mechanism of action of Bendamustine
by: Bagnobianchi, A.
Published: (2015)

Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region
by: Francesco Autore, et al.
Published: (2020-06-01)

SYNTHESIS OF BENDAMUSTINE HYDROCHLORIDE IN FLOW MICROREACTOR
by: A. Moldavsky, et al.
Published: (2019-01-01)

Bendamustin v terapii nekhodzhkinskikh limfom
by: A A Semenova
Published: (2012-06-01)

Bendamustine Associated with Irreversible Ascending Paralysis
by: Ashraf Alhafez, et al.
Published: (2013-01-01)

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study
by: Antonio Cuneo, et al.
Published: (2020-11-01)

Inhibition of autophagy enhances the anticancer effect of enzalutamide on bladder cancer
by: Yongjun Quan, et al.
Published: (2019-12-01)

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
by: Ana-Alicia López-Iglesias, et al.
Published: (2017-06-01)

Comparison of the cytotoxic mechanisms of anti-CD20 monoclonal antibodies Rituximab and GA101 in Chronic Lymphocytic Leukemia
by: Reslan, Lina
Published: (2010)

New Approaches to Improving Bendamustine Microractor Synthesis
by: A. L. Moldavsky, et al.
Published: (2020-02-01)

Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael M, et al.
Published: (2010-01-01)

Herpetic esophagitis following bendamustine-containing regimen
by: Yamane H, et al.
Published: (2016-06-01)

Experience with the use of bendamustine (Rozustin®): safety and efficacy
by: A. A. Semenova, et al.
Published: (2020-10-01)

Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation
by: Jessica Stokes, et al.
Published: (2021-04-01)

Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell-dependent graft-versus-leukemia
by: Jessica Stokes, et al.
Published: (2020-01-01)

Drug Nanorod-Mediated Intracellular Delivery of microRNA-101 for Self-sensitization via Autophagy Inhibition
by: Xiaofei Xin, et al.
Published: (2019-09-01)

Relationship between triterpenoid anticancer drug resistance, autophagy, and caspase-1 in adult T-cell leukemia
by: Tsukasa Nakanishi, et al.
Published: (2016-05-01)

Bendamustine in the treatment of B-cell non-Hodgkin lymphoma
by: L G Babicheva, et al.
Published: (2018-12-01)

Bendamustine in the treatment of non-Hodgkin&rsquo;s lymphomas
by: Fredrick Hagemeister, et al.
Published: (2009-12-01)

Skin testing with bendamustine: what concentration should be used?
by: Laura Malinauskiene, et al.
Published: (2020-07-01)

The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
by: Ibrahim T Aldoss, et al.
Published: (2009-11-01)

Severe Dermatologic Reactions with Bendamustine: A Case Series
by: Allison Carilli, et al.
Published: (2014-07-01)

Targeting Autophagy Triggers Apoptosis and Complements the Action of Venetoclax in Chronic Lymphocytic Leukemia Cells
by: Damjan Avsec, et al.
Published: (2021-09-01)

Promyelocytic Leukemia Restricts Enterovirus 71 Replication by Inhibiting Autophagy
by: Deyan Chen, et al.
Published: (2018-06-01)